Search hospitals
>
Ontario
>
TORONTO
The Hospital for Sick Children
Claim this profile
TORONTO, Ontario M5G 1X8
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for Solid Tumors
Conducts research for Neuroblastoma
Conducts research for Leukemia
964 reported clinical trials
83 medical researchers
Summary
The Hospital for Sick Children is a medical facility located in TORONTO, Ontario. This center is recognized for care of Brain Tumor, Cancer, Solid Tumors, Neuroblastoma, Leukemia and other specialties. The Hospital for Sick Children is involved with conducting 964 clinical trials across 1,292 conditions. There are 83 research doctors associated with this hospital, such as Daniel Morgenstern, MBChir, Eric Bouffet, MD, Vijay Ramaswamy, and Glenda Courtney-Martin, PhD.
Area of expertise
Brain Tumor
The Hospital for Sick Children has run 83 trials for Brain Tumor. Some of their research focus areas include:
Cancer
The Hospital for Sick Children has run 82 trials for Cancer. Some of their research focus areas include:
Top PIs
Daniel Morgenstern, MBChir
Hospital for Sick Children
4 years of reported clinical research
Eric Bouffet, MD
The Hospital for Sick Children (SickKids)
1 year of reported clinical research
Vijay Ramaswamy
Hospital for Sick Children
7 years of reported clinical research
Glenda Courtney-Martin, PhD
The Hospital For Sick Children
1 year of reported clinical research
Clinical Trials running at The Hospital for Sick Children
Neuroblastoma
Testicular cancer
Crohn's Disease
Sickle Cell Disease
Cancer
Chronic Kidney Disease
Ulcerative Colitis
Inflammatory Bowel Disease
Von Willebrand Disease
Nephrotic Syndrome
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting
2 awards
Phase 3
7 criteria
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting
2 awards
Phase 3
22 criteria
Naxitamab
for High-Risk Neuroblastoma
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Recruiting
1 award
Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Hospital for Sick Children?
The Hospital for Sick Children is a medical facility located in TORONTO, Ontario. This center is recognized for care of Brain Tumor, Cancer, Solid Tumors, Neuroblastoma, Leukemia and other specialties. The Hospital for Sick Children is involved with conducting 964 clinical trials across 1,292 conditions. There are 83 research doctors associated with this hospital, such as Daniel Morgenstern, MBChir, Eric Bouffet, MD, Vijay Ramaswamy, and Glenda Courtney-Martin, PhD.
Where is The Hospital for Sick Children located?
**The Hospital for Sick Children (SickKids)** - **Location:** Downtown Toronto, University Avenue, between Gerrard and Elm streets. Main entrance at 170 Elizabeth St. - **Transport:** Accessible by subway on the University-Spadina line (Line 1). Exit at Queen's Park station and walk one block south or St. Patrick station and walk two blocks north.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at The Hospital for Sick Children, contact the Financial Information Center at 800-787-0021 option 6. Assistance is available for uninsured, underinsured, or those ineligible for government programs, based on family income, residency, and medical necessity. Required documentation for full assistance includes gross monthly family income, proof of ineligibility for government programs, identification, proof of address, and school verification for patients if applicable.
What insurance does The Hospital for Sick Children accept?
The Hospital for Sick Children accepts a variety of insurance plans, including All Kids, FamilyCare, and Medicaid. Coverage includes a comprehensive range of services: doctor and clinic services, dental, emergency, hospital and maternity care, surgeries, medications, lab and X-ray, mental health and substance abuse treatment, family planning, medical supplies and equipment, transportation for emergency care, home health services, early intervention, audiology, optometry, podiatry, chiropractic, care for developmental disabilities, skilled pediatric nursing, nursing home services, regular checkups and vaccinations for children, renal dialysis, nursing care, physical, occupational, and speech therapy, hospice care, and respiratory equipment. Eligible families may receive assistance with transportation for medical appointments.
What awards or recognition has The Hospital for Sick Children received?
The Hospital for Sick Children (SickKids) in Toronto is renowned for its extensive research contributions and advanced patient care, making it one of Canada's leading research-intensive hospitals. It houses Canada's largest hospital-based child health research institute, the SickKids Research Institute, which is at the forefront of groundbreaking research that benefits children worldwide. SickKids has been awarded $17.9 million by the Canada Foundation for Innovation for research projects aimed at understanding memory formation, enhancing genomics capacity, and advancing precision child health, and collaborates with notable organizations to develop cutting-edge children's hospitals and research centers.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.